权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Hepatic kisspeptin receptor signaling in nonalcoholic fatty liver

非酒精性脂肪肝中的肝脏 Kisspeptin 受体信号传导

基本信息

批准号：
10389827
负责人：
Stephania Guzman
金额：
$ 3.6万
依托单位：
RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-01-01 至 2022-10-21
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10389827
关键词：
Affect Agonist Alcohols Binding Biochemical Bioinformatics Biology Blood Cicatrix Cirrhosis Clinical Clinical Data Coupled Data Deuterium Development Diet Disease Exhibits Fatty Liver Fatty acid glycerol esters Fibrosis GDF15 gene GTP-Binding Proteins Goals Hepatic Hepatocyte High Fat Diet Homeostasis Inflammation Inflammatory Insulin Resistance KISS1 gene KISS1R gene Knockout Mice Lead Ligands Lipids Liver Liver Fibrosis Mass Spectrum Analysis Mediator of activation protein Messenger RNA Metabolic Metabolic Diseases Metabolic syndrome Molecular Morbidity - disease rate Mus Non-Insulin-Dependent Diabetes Mellitus Obesity Obesity Epidemic Pathogenesis Pathway interactions Patients Peptides Persons Pharmaceutical Preparations Pharmacology Pharmacotherapy Plasma Prevalence Preventive treatment Primary carcinoma of the liver cells Proteins Receptor Activation Receptor Signaling Research Personnel Role Signal Transduction Source Steatohepatitis Testing Tissues Triglycerides Water Work chronic liver disease comorbidity fibroblast growth factor 21 gain of function improved in vivo inflammatory marker lipid biosynthesis lipid metabolism liver development liver transplantation metabolomics mortality mouse model non-alcoholic fatty liver non-alcoholic fatty liver disease nonalcoholic steatohepatitis novel prevent receptor sensor therapeutic development therapeutic target

项目摘要

PROJECT SUMMARY The increasing prevalence of obesity in the U.S.A. is associated with metabolic comorbidities such as type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD), a disease characterized by excess liver fat accumulation in people who drink little to no alcohol. Although there are many medications approved for T2D, no medications are approved for NAFLD, which is now the leading cause of chronic liver disease and fastest-growing reason for liver transplantation. The first stage of NAFLD is steatosis (fatty liver), that can progress to non- alcoholic steatohepatitis (NASH) where fat accumulation in the liver is associated with inflammation and scarring. As the liver cells are gradually replaced by scar tissue, the liver stops functioning properly. The liver produces a peptide known as kisspeptin (KP) that circulates in the blood. KP binds a protein known as the kisspeptin 1 receptor (KISS1R). Although KISS1R is expressed in the liver, its function is unknown. Our new pilot data has revealed that KP/KISS1R signaling can inhibit fat accumulation in the liver. Using genetically modified mouse models and plasma derived from NAFLD patients, the proposed work will determine whether KISS1R signaling prevents the development of NAFLD and the underlying mechanisms. In Aim 1, we will investigate the mechanisms by which hepatic KISS1R signaling inhibits lipogenesis. In Aim 2, we will determine the effect of increasing KISS1R signaling on the development of NASH and fibrosis. Collectively, these clinically translational findings may identify KISS1R as a novel target for the preventive treatment against the development of NAFLD.

项目总结